Compass Pathways conducts world’s largest psilocybin therapy trial
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin
June 28, 2021
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin
Psychedelic VR meditation startup Tripp raises $11 million Series A Looking for a spiritual awakening
Marley One Launches The First Global Functional And Psychedelic Mushroom Brand Don’t worry about a
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia
Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’ PDF
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board Are psychedelics the future
Red Light Holland to Partner with Leading Fresh and Dried Mushroom Producers on East Coast
Roth says Mydecine Innovations has blockbuster potential with its MYCO-001 psychedelic therapy as it initiates
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics Revive
Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial While there have been few
atai Life Sciences Announces Pricing of Upsized Initial Public Offering Atai Life Sciences (ATAI), a
Here to Serve Holding Corp. Acquires 15% Ownership in Kaiyon Biotech Inc., a Psilocybin Biotech
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004 Cybin Inc. (CYBN) announced that
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel
Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program
Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent Vocan Biotechnologies Inc., a subsidiary of Core
Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms Mydecine Innovations Group
Field Trip Health Ltd. Applies to List Its Common Shares on the NASDAQ Stock Market
Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout
Psychedelic Mushroom Shops Reach The Americas Many psychedelic companies are being drawn to Jamaica, one
Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003 Cybin announced that its proprietary
Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027 A recent report
Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test Entheon Biomedical Corp. launched the first psychedelics